Ifosfamide (IFA) (Brock, 1968) , an isomer of the established clinical anti-tumour and immunosuppressive drug cyclophosphamide (CPA) (Arnold et al., 1958; 1961) , has been used in recent years against many human cancers (Burkert, 1977) . Our earlier studies in mice (Struck, 1976) and dogs (Hill et al., 1973) included the first report of identification of isophosphoramide mustard (IPM) as a metabolite of IFA, and the presence of this metabolite in plasma of patients treated with IFA was recently described (Bryant et al., 1980) . Chemotherapy with IFA and CPA is frequently limited by their urotoxicity, and acrolein, a common metabolite discovered by Alarcon et al., (1972) , has been implicated as the causative agent of this toxicity Cox, 1979) .
IPM was synthesized and evaluated against a spectrum of experimental leukaemias and solid tumours to determine whether it is potentially responsible for the anti-tumour effect of IFA in vivo.
Materials and methods
Starting materials Phenyl phosphorodichloridate, acetone:chloroform (1:3, 2 developments): IFA, 0.40; 4-ketoifosfamide, 0.65; dechloroethylcyclophosphamide and -ifosfamide, 0.13; 4-hydroxyifosfamide, 0.10; alcoifosfamide, 0.05. The Rf value of both carboxyifosfamide and IPM, as their methyl esters, was 0.7 in acetone:chloroform (3:1). Under these conditions, 0.5 pg of these standards can be detected.
Alkylating activity Thin-layer chromatograms were sprayed with a 1% solution of 4-(pnitrobenzyl)pyridine (NBP, Aldrich Chemical Co.) in acetone, heated in an oven for 15 min at 140°C, and sprayed with a 3% solution of potassium hydroxide in methanol. Alkylating components yielded blue spots.
Anti-tumour evaluation All compounds were evaluated in murine tumour models in accordance with protocols established by the National Cancer Institute (Geran et al., 1972) . With the L1210 and P388 leukeamias, the tumours were maintained in DBA/2 mice and passaged weekly by the i.p. transplantation of quantified ascitic leukaemia cells into healthy 10-to 12-week old mice. For the chemotherapy trials, 5-to 7-week old hybrid mice of the CDF1 (BALB/cxDBA/2) strain were used. Drugs were dissolved in physiological saline and were administered i.p. 24 or 48 h after implantation of leukaemia cells. All experiments included a range of drug dose levels, 10 mice/group, and the leukaemia inoculum was titrated down to one cell by dilution, to provide for estimation of tumour cell doubling time and the calculation of tumour cell kill .
The B16 melanoma, M5076 ovarian tumour, and Lewis lung carcinoma were maintained in C57BL6 mice (host of origin). For experimentation, B6D2F1 (C57BL/6 x DBA/2) mice were used. The mammary 16/C tumour was maintained in C3H mice and for experimentation C57BL/6 x C3H mice were used. .
Colon tumour 06/A was maintained in BALB/c mice, and the host for chemotherapy was CDF1 (BALB/c x DBA/2) mice. The techniques of chemotherapy and data analysis have been presented in detail elsewhere 1979; Schabel et al., 1977 Blood was stored on ice until collection for each time period was complete. Blood samples (vol. approximately 10 ml from each time period and from 0.2-0.6ml/mouse) were immediately extracted with chloroform followed by methanol with diazomethane treatment of the methanol extract as described previously (Alberts et al., 1978) . Under the conditions of the assay, only 4-hydroxy-ifosfamide was observed to be unstable, thus accounting for our failure to detect it in this study. Dog urine was collected by catheter and frozen on dry ice immediately upon collection. 3 g ). The syrup in ethanol (absolute, 20 ml) was treated with platinum oxide catalyst (250 mg) and hydrogenated in a Parr hydrogenation apparatus with shaking for 5 h at room temperature and 50 lbs in 2 pressure. The reaction mixture, which contained a white, crystalline precipitate, was filtered to collect the catalyst and precipitate. The filtrate was concentrated in vacuo to 10 ml and filtered to collect a white, crystalline precipitate (melting point, 137-8°; 230mg after drying in vacuo). The catalystprecipitate mixture was extracted with warm ethanol (2 x 1Oml). The combined washings, after filtration, were concentrated in vacuo to 10ml and filtered to collect a white, crystalline precipitate (melting point, 137-80; 240mg after drying in vacuo). Analysis of this sample gave the following data: carbon-hydrogen-nitrogen (CHN) analysis: C, 21.74; H, 5.02; N, 12.81; theory: C, 21.74; H, 5.02; N, 12.67; infrared spectrum (cm-l): 3400, 3300, 2900, 2700, 2540, 2430, 2400, 1570, 1440, 1430, 1400, 1370, 1360, 1335, 1305, 1290, 1260, 1240, 1170, 1130, 1090, 1015, 940, 910, 870, 835, 775, 680, 660, 650, 550, 490, 465, 420, 385, 355, 335 ; proton magnetic resonance in dimethyl sulphoxide with tetramethylsilane as the internal reference: chemical shift (ppm) 2.90-3.15 (4H, quintuplet, -NH-CH2-), 3.50-3.65 (4H, triplet, -CH2Cl), 6.50 (3H, broad singlet, -NH-, -OH); mass spectrum: field desorption: mass/charge ratio (m/z) 221 Metabolism of IFA to IPM in vivo chloroform and methanol extracted all of the radioactivity from 3 blood samples, taken from groups of mice administered 14C-IFA. TLC of the chloroform extracts along with synthetic standards identified 4-ketoifosfamide, dechloroethyl cyclophosphamide (Bakke et al., 1972 ), dechloroetflvlifosfamide (Norpoth, 1976 , alcoifosfamide, and unchanged drug (Struck, 1976 TLC of the methanol extracts with synthetic standards IPM and carboxyifosfamide (Hill et al., 1973) as their methyl esters identified these 2 metabolites in each extract. Carboxyifosfamide, which was readily detectable by mass spectral analysis at 10 and 30 min, was barely detectable after 60min. Mass spectral analysis indicated that IPM increased from 10-30min and declined from 30-60min but not as rapidly as carboxyifosfamide.
Results

Synthesis
A chloroform extract of 0-12 h urine from a beagle dog given 20mgkg -of 14C-IFA was separated by TLC in chloroform:methanol (95:5). Mass spectral analysis of a methanol eluate of a radioactive, alkylating band of Rf 0.1 identified 4-ketoifosfamide (Hill et al., 1973) , alcoifosfamide and the 2 monodechloroethylated isomers of ifosfamide (Norpoth, 1976) . As reported previously, IFA and carboxyifosfamide were also identified in dog urine (Hill et al., 1973) .
These results, coupled with earlier studies by us (Hill et al., 1973) and others (Bryant et al., 1980; Hohorst, 1977; Norpoth, 1976 , Takamezawa et al., 1974 in experimental animals and humans are consistent with the metabolic pathway shown in the Figure 1 .
Antitumour activity Table I Table II , IPM retained its activity against a line of L1210 leukaemia that was partially resistant to CPA and IFA.
IPM was active against CPA-sensitive P388 leukaemia, and retained most of its activity against a line of P388 leukaemia that was partially resistant to CPA and IFA (Table III) e.g., a 6-log10 reduction= 99.9999% decrease in viable leukaemia cells . ISee footnote , Table I . (Table IV) .
Comparison of the response of Lewis lung carcinoma to IPM, CPA, IFA, and PM gave the results shown in Table V . Responses were essentially equivalent to all the drugs except PM, which was much less active on both single and multiple dose schedules. Combination of CPA (100mgkg-1) with either single dose treatment of IPM (100mg kg-1) or multiple dose treatment with PM (30mgkg-1 dose, every (q) 5minx7) resulted in 9/9 or 6/9 tumourfree survivors, respectively. These responses were equivalent to that given by a single dose of CPA (200mg/kg), which gave 9/10 survivors.
Responses of mammary adenocarcinoma 16/C s.c. to IPM and CPA are compared in Table VI . The results demonstrate that IPM is at least as active as CPA against this highly metastatic murine tumour.
Comparison of the activity of IPM with that of cyclophosphamide, IFA, and PM against B16 $The Log1o cell kill (total) was calculated from the following formula: Log kill = T-C value/(3.32) (Td). Where Td is the tumour volume-doubling time measured from a best fit straight line of the control-group tumours in exponential growth (100-400mg range). Td = 1.8 for 16/C in this experiment. IPM was, however, at least as active as CPA based on tumour growth delay to 1250mg (T-C) and increase in life span over that of untreated controls (ILS) (IPM= 14 day T-C, 116% ILS compared with CPA=6.3 day T-C, 58% ILS).
Evaluation of IPM was performed against a single rat tumour, Yoshida ascitic sarcoma, the signal tumour used to select candidate oxazaphosphorines for further investigations (Arnold et al., 1961) . Results are shown in Table VIII . Several times were compared with those of control mice receiving titrated numbers of cells from a cell suspension incubated without drug, and the results are shown in Table IX. Acrolein was the most cytotoxic agent, causing a 4- 1  <1  <1  <1  <1  1  <1  <1  <1  4  10  I  <1  <1  <1  4  100  1  3  1  5  >7  102  0.1  10  <1  <1  <1  1  1  10  <1I  <1   1  1  10  10  <1  <1  1  7  100  10  6  3  7  >7  103  0.1  100  <1  <1  <1  <1  I  100  <1  <1  <1  <1  10  100  5  2  6  >7  103  100  100  >7  7  >7  >7  104 Drugs were incubated with 2.5 x 107 cells/ml in physiological saline at 35°C. Mutagenic activity IPM and 2-chloroethylamine, a potential hydrolytic decomposition product of both IPM and carboxyifosfamide in vivo, were compared in the Ames mutagenicity test (Ames et al., 1975) with PM and bis(2-chloroethyl)amine, products of metabolism or hydrolytic degradation of CPA or its metabolites (Jardine et al., 1978) . The results (data not presented) indicate greater mutagenic activity for these alkylating metabolites of CPA [PM and bis(2-chloroethyl)amine] than for those of IFA [IPM and 2-chloroethylamine].
Discussion IPM was synthesized in satisfactory yield by reaction of phenyl phosphorodichloridate with 2-chloroethylamine followed by catalytic hydrogenolysis of the phenyl group. Although the synthesis of IPM has not been described previously, it was prepared in 1968 by Brock & Arnold (private communication) , and several reports of its chemical and toxicological properties were reported previously (Brock & Hohorst, 1977; Brock et al., 1979; Hohorst, 1977; Rauen & Schriewer, 1971) .
Investigation of the metabolism of IFA in experimental animals and in humans has established the metabolic pathway shown in Figure  1 . As expected, no major qualitative differences in metabolism of IFA and CPA were observed. The isonieric structure of IFA results in the production of N-dechloroethylifosfamide, a metabolite identified by Norpoth et al. (1976) in humans, by Takamizawa et al. (1974) in rabbits, and by us (Struck, 1976) (Brock & Hohorst, 1977; Colvin et al., 1976 , Cox et al., 1975 , Domeyer & Sladek, 1980 Brock & Hohorst (1977) insist that the selectivity for tumour toxicity resides exclusively with 4-hydroxy CPA and 4-hydroxy-IFA (or the isomeric aldophosphamide and aldoifosfamide). Others (Colvin et al., 1976; Cox et al., 1975; Domeyer & Sladek, 1980 : Hilton et al., 1981 Sladek, 1977; Sladek et al., 1981; Sladek & Powers, 1980) are totally or partially in agreement with this view and suggest that the hydroxylated metabolites are at least important extracellular determinants of antitumour activity. In contrast, some (Friedman et al., 1976; Struck et al., 1975) have suggested that the total or dominant cytotoxicity is controlled by extracellular PM and IPM, a view consistent with the high, CPA-and IFA-comparable, antitumour activity reported herein.
Because of certain observations on DNA crosslinking (Hilton et al., 1981) and cellular transport (Lenssen & Hohorst, 1979) , it could be suggested that the mechanisms of action of extracellular PM and of 4-hydroxycyclophosphamide are different. The superiority of 4-hydroxycyclophosphamide (or its precursor 4-hydroperoxycyclophosphamide) to PM and IPM in vitro has been observed in most evaluations (Brock & Hohorst, 1977; Hilton et al., 1981; Sladek & Powers, 1980) , including our own (Table VIII) , whereas in vivo the differences in many evaluations (Friedman et al., 1976; Ramonas et al., 1981) but not all (Brock & Hohorst, 1977) Domeyer & Sladek (1980) and Cox et al. (1975) or by pharmacokinetic properties as we have done. Data presented herein (Tables I-VIII) indicate comparable selectivity for tumour toxicity in vivo for IPM, CPA, and IFA at comparable host toxicity (LD10). The extensive data of Friedman, et al. (1976) , in which PM was compared with CPA against 25 experimental tumours, demonstrated that PM was of comparable or superior activity against 18 of them; these data, coupled with those included herein, clearly demonstrate that extracellularlydelivered PM and IPM are effective agents, in many cases with anti-tumour activity and selectivity in vivo comparable to CPA and IFA and their 4-hydroxy and 4-hydroperoxy derivatives. Because these data (Friedman et al., 1976 , and those reported herein) can essentially account for the antitumour activity of the parent drugs in vivo, it seems reasonable to assume that PM and IPM, delivered to tumour cells by circulation, contribute significantly, if not dominantly or exclusively in some cases, to the observed activity of the parent drugs and the primary metabolites. Their antitumour effect in vivo suggests that either they participate directly in tumour cytotoxicity as extracellulary-delivered metabolites of their parent drugs, or that they are acting by a mechanism different from that of the parent drugs and primary metabolites.
The mutagenicity of IPM and a potential hydrolytic product, 2-chloroethylamine, was found to be less than that of PM and its hydrolytic product, bis(2-chloroethyl)amine. These results suggest reduced likelihood of mutagenic transformation after treatment with IFA or IPM in comparison with CPA or PM.
Haemorrhagic cystitis frequently results from treatment of patients with CPA and IFA (Morgan et al., 1981; Scheef et al., 1979) , and this toxic effect has been attributed to the metabolite acrolein Cox, 1979) . 4-Hydroxycyclophosphamide and 4-hydroxyifosfamide and the corresponding hydroperoxy derivatives similarly yield acrolein upon decomposition. An advantage of PM and IPM is their inability to generate this toxic metabolite, although various methods have been reported (Morgan et al., 1981; Scheef, et al., 1979) to control acrolein toxicity. Direct instillation of the phosphorodiamidic acids into bladders of experimental animals demonstrated the absence of generation of urotoxicity in comparison with acrolein. Acrolein has also been shown to cause denaturation of hepatic microsomal cytochrome P-450 (Marinello et al., 1978) and to be embryotoxic in rabbits (Claussen et al., 1980) . IPM is an active alkylating agent and, like PM (Colvin et al., 1976; Struck et al., 1975) , requires no additional activation. As such, variability in activation, which is possible after administration of parent drug, is eliminated. Chemically, IPM appears to be more resistant to hydrolytic deactivation than PM. Brock & Hohorst (1977) and Hohorst (1977 reported a hydrolysis half-life of both 840min and 2.6 h for IPM, compared to 48 min, 180 min, and 542min for PM, 4-hydroxycyclo phosphamide, and 4-hydroxyifosfamide, respectively, in 0.07 M phosphate buffer at 37°C.
Precise quantitative data have not yet been obtained for the pharmacokinetics of IPM, but our results demonstrate faster clearance of optimum levels of L1210 cell killing factor(s) than occurs with CPA and IFA. This property could be disadvantageous in that tumour cell exposure to the cytotoxic agent is less than for parent drug, thus possibly requiring a divided-dose schedule for optimum response against some tumours. Faster clearance could also be advantageous in that general systemic exposure to the alkylating agent would be reduced, possibly resulting in less toxicity than that caused by parent drug. This investigation was supported by Grant Number CA 26632 from the National Cancer Institute, NIH, DHHS.
